GlassScriptPhysician profile
Kristin Staniszewski
NPI 1992702468
$15,415.08
in general payments reported to CMS, 2019-2025
35 companies · $3,173 in 2025
The $3,173 reported for 2025 was more than what 97% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,710 · 2022: $2,885 · 2023: $2,988 · 2024: $3,659 · 2025: $3,173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,820.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,819.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,601.76 | 2021-2025 | |
| Amgen INC. | $2,447.10 | 2021-2025 | Krystexxa, Evenity, Enbrel |
| Pfizer INC. | $1,261.33 | 2021-2025 | |
| Janssen Biotech, INC. | $1,110.24 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Ucb, INC. | $978.42 | 2021-2025 | Cimzia, Bimzelx |
| Astrazeneca Pharmaceuticals LP | $832.92 | 2021-2025 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $817.78 | 2021-2025 | |
| Lilly USA, LLC | $602.25 | 2021-2024 | Taltz, Zepbound |
| Ani Pharmaceuticals, INC. | $565.82 | 2022-2025 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $532.81 | 2021-2023 | Krystexxa |
| Fresenius Kabi USA, LLC | $366.37 | 2023-2025 | Idacio, Tyenne |
| Genzyme Corporation | $339.13 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $289.95 | 2021-2025 | Strensiq |
| E.R. Squibb & Sons, L.L.C. | $264.47 | 2021-2025 | Orencia |
| Glaxosmithkline, LLC. | $223.42 | 2021-2024 | Benlysta |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $139.15 | 2021-2024 | Cyltezo |
| Genentech USA, INC. | $119.46 | 2021-2025 | Actemra |
| Sanofi-Aventis U.S. LLC | $88.60 | 2022 | |
| Organon LLC | $88.05 | 2022-2025 | Hadlima |
| Octapharma USA, INC. | $82.99 | 2025 | Octagam Immune Globulin (Human) |
| Ferring Pharmaceuticals INC. | $77.05 | 2022-2024 | Euflexxa |
| Mallinckrodt Hospital Products INC. | $76.16 | 2024-2025 | Acthar |
| Actelion Pharmaceuticals US, INC. | $74.19 | 2021-2024 | Opsumit, Uptravi |
| Radius Health, INC. | $65.28 | 2021-2023 | |
| Sobi, INC | $63.18 | 2021-2022 | |
| Aurinia Pharma U.S., INC. | $59.49 | 2022-2024 | Lupkynis |
| Teva Pharmaceuticals USA, INC. | $35.17 | 2023-2024 | Truxima |
| Pacira Therapeutics, INC. | $34.05 | 2021 | |
| Fidia Pharma USA INC. | $33.66 | 2025 | Hymovis |
| Almatica Pharma LLC | $32.46 | 2025 | Teriparatide |
| Ultragenyx Pharmaceutical INC. | $29.53 | 2022 | |
| Biogen, INC. | $24.73 | 2024 | |
| Tonix Medicines, INC. | $21.41 | 2025 | Tonmya |
| Sandoz INC. | $18.94 | 2023 | Hyrimoz |
| Scilex Pharmaceuticals INC. | $17.76 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristin Staniszewski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.